Company Encyclopedia
View More
name
HISUN
600267.SH
Zhejiang Hisun Pharmaceutical Co., Ltd. engages in the research, development, production, and sale of biological and generic drugs in China. The company provides active pharmaceutical ingredients and finished dosage form products. It offers products for anti-tumor, anti-infection, cardiovascular, endocrine, immunosuppression, antidepressant, liver care, and orthopaedics treatment; and weight loss, anti-viral, anti-TB, animal healthcare, and others.
3.157 T
600267.SHMarket value -Rank by Market Cap -/-

Financial Score

05/12/2025 Update
B
PharmaceuticalsIndustry
Industry Ranking25/223
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreB
    • ROE6.52%C
    • Profit Margin5.56%C
    • Gross Margin48.88%B
  • Growth ScoreC
    • Revenue YoY3.02%C
    • Net Profit YoY2801.47%A
    • Total Assets YoY-5.78%D
    • Net Assets YoY3.06%C
  • Cash ScoreB
    • Cash Flow Margin1798.67%B
    • OCF YoY3.02%C
  • Operating ScoreB
    • Turnover0.62B
  • Debt ScoreC
    • Gearing Ratio42.84%C

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Hisun Pharmaceutical Publicly Lists Subsidiary Zhejiang Pharmaceutical

    Hisun Pharmaceutical Publicly Lists Subsidiary Zhejiang Pharmaceutical

    marketscreener·
    SH
    600267
    -0.38%
    marketscreener·
    SH
    600267
    -0.38%

    Zhejiang Hisun Pharmaceutical Obtains China Veterinary Nod for Two Drugs

    Zhejiang Hisun Pharmaceutical Obtains China Veterinary Nod for Two Drugs

    marketscreener·
    SH
    600267
    -0.38%
    marketscreener·
    SH
    600267
    -0.38%

    Hisun Pharmaceutical Gets Approval for Two Veterinary Drugs

    Hisun Pharmaceutical Gets Approval for Two Veterinary Drugs

    marketscreener·
    SH
    600267
    -0.38%
    marketscreener·
    SH
    600267
    -0.38%

    HISUN: Has cumulatively spent CNY 56.9915 million to repurchase 0.51% of its shares

    HISUN announced that the company will commence its fourth share repurchase through centralized bidding starting from May 12, 2025, with the repurchase period ending on May 11, 2026. The expected amount is between 50 million yuan and 100 million yuan, intended for the employee stock ownership plan or equity incentive. As of the end of October 2025, the company has cumulatively repurchased 6,115,000 shares, accounting for 0.51% of the total share capital, with a total payment of 56.9915 million yuan, and the repurchase price ranging from 8.92 yuan/share to 10.55 yuan/share, in line with the established plan

    Zhitong·
    SH
    600267
    -0.38%
    Zhitong·
    SH
    600267
    -0.38%

    On the morning of the second day of the National Conference in 2025: Shenghe Pharmaceutical, HISUN, and other pharmaceutical companies enter the venue

    The negotiations for the national medical insurance catalog in 2025 entered their second day. Reporters observed that around 7:30 AM, companies were already waiting outside the National People's Congress conference center. Information verification for entry began around 8:00 AM. The companies participating in the negotiations this morning included Shenghe Pharmaceutical, HISUN, and Sanofi

    Zhitong·
    US
    SNY
    -1.59%
    SH
    600267
    -0.38%
    US
    SNYNF
    0.00%
    Zhitong·
    US
    SNY
    -1.59%
    SH
    600267
    -0.38%
    US
    SNYNF
    0.00%
    © 2025 Longbridge｜Disclaimer